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Abstract
Cerebral cavernous malformations (CCMs) are clusters of dilated capillaries that affect around 
0.5% of the population. CCMs exist in two forms, sporadic and familial. Mutations in 3 
documented genes, KRIT1 (CCM1), CCM2 and PDCD10 (CCM3), cause the autosomal dominant 
form of the disease, and somatic mutations in these same genes underlie lesion development in the 
brain. Murine models with constitutive or induced loss of respective genes have been applied to 
study disease pathobiology and therapeutic manipulations. We aimed to analyze the phenotypic 
characteristic of two main groups of models, the chronic heterozygous models with sensitizers 
promoting genetic instability, and the acute neonatal induced homozygous knockout model. Acute 
model mice harbored a higher lesion burden than chronic models, more localized in the hindbrain, 
and largely lacking iron deposition and inflammatory cell infiltrate. The chronic model mice 
showed a lower lesion burden localized throughout the brain, with significantly greater perilesional 
iron deposition, immune B and T cell infiltration, and less frequent junctional protein 
immunopositive endothelial cells. Lesional endothelial cells in both models expressed similar 
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phosphorylated myosin light chain immunopositivity indicating Rho-associated protein kinase 
activity. These data suggest that acute models are better suited to study the initial formation of the 
lesion, while the chronic models better reflect lesion maturation, hemorrhage and inflammatory 
response, relevant pathobiologic features of the human disease.
Cerebral cavernous malformation (CCM) is a common neurovascular disorder predisposing 
approximately 0.5 % of the population to a lifetime risk of hemorrhagic stroke, focal 
neurological deficits and seizures.1–4 The disease can arise sporadically with solitary 
lesions, or is inherited in an autosomal dominant pattern, with mutations affecting one of the 
three documented CCM genes, namely KRIT1 (CCM1), CCM2 and PDCD10 (CCM3).5–7 
Many studies have been published about the natural course of the disease and the lifetime 
risk of morbidity and mortality.4 However, the ability to accurately predict or modify lesion 
behavior in the clinical setting remains problematic.
In vitro experiments and animal models examining the loss of CCM gene expression have 
contributed significantly to our understanding of disease pathobiology.8–13 These include 
activation of Rho-associated protein kinase (ROCK),14 resulting in disrupted endothelial 
cell-cell junctions and hyper-permeability of the blood-brain barrier.10, 15–17 These are 
associated with repetitive hemorrhages and perilesional iron deposition, mediating clinical 
manifestations.18–21 A defined B and T cell mediated immune response has been reported to 
modulate the clinical course of the disease in human and murine models,22–24 and several 
studies have shown that inflammation may promote CCM development.25–28
Mice with genetic mutations of Krit1, Ccm2, and Pdcd10 have been generated, and 
constitutive deletion of both copies of these genes lead to embryonic lethality, with defects 
in cardiac development.29–31 Two general strategies have been used to circumvent this 
embryonic lethality. One approach uses mice with heterozygous Ccm mutations, and these 
develop lesions in all regions of the brain as the mice age, especially when bred in a 
background predisposing to somatic mutations (p53 or Msh2 genes loss).9 These have been 
referred to as “chronic models”. Brains in these models recapitulate various features of the 
human autosomal dominant disease, including the stochastic development of new lesions 
over time. Lesions include primordial dilated capillaries and more mature multi-cavernous 
lesions, and they manifest other phenotypic signatures of the human disease, including 
increased blood-brain barrier permeability, defective endothelial cell-cell junctions, iron 
deposition, and immune cell infiltration.8, 9, 32, 33 These models have already been used for 
the pre-clinical testing of therapeutic agents.8, 11, 34
CCM lesions can also be generated with great efficiency in the developing hindbrain and 
retinas with endothelial-specific tamoxifen-inducible Cre expression leading to homozygous 
loss of Krit1, Ccm2 or Pdcd10 genes in the immediate postnatal period.14, 30, 32, 35, 36 In 
these “acute models”, injection of tamoxifen in neonatal mice (at postnatal days 1 to 3) leads 
to homozygous deletion of CCM genes in endothelial cells. Lesions with similar histology 
as CCM develop within a few days in the hindbrain and retina, where ongoing 
vasculogenesis lags into the postnatal period. These animals do not typically survive into 
adulthood, but the models have been used very effectively to demonstrate several molecular 
signaling aberrations driving CCM lesion genesis.14, 37
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It remains unclear to what extent the acute models manifest the same phenotypic features as 
chronic lesions or the human disease. The number and volumetric lesion burden, maturation 
of lesions, cellular changes in lesional endothelial cells, iron deposition, and involvement of 
immune cells have not been studied systematically in the acute and chronical models. The 
potential differences will influence what aspects of disease are best modeled by each 
approach. Our current study aim to fill this knowledge gap by directly comparing lesion 
phenotypes in these two general classes of CCM murine models.
Material and methods
Transgenic CCM murine models
Six distinct Mus musculus transgenic CCM models were studied, and defined as acute (3 
different genotypes) or chronic (3 different genotypes) models. Guidelines stated in the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH 
Publications No. 8023, revised 1978) have been followed, and all animal studies have 
complied with the Animal Research: Reporting of In Vivo Experiments guidelines. Acute 
models were bred at University of Pennsylvania or the University of California at San Diego, 
and chronic models at Duke University. Following brain extraction and fixation, specimens 
were sent to a common phenotyping core laboratory at the University of Chicago for 
imaging and histological analyses.
Cdh5iCreERT2Krit1ECKO acute model—Cdh5CreERT2Krit1fl/fl mice were generated by 
breeding Cdh5CreERT2 and Krit1fl/fl mice as previously reported.14 All mice were maintained 
on a mixed 129Sv/C57Bl6 background. At 1-day post-birth, 40 μg of 4-hydroxytamoxifen 
(H7904, Sigma Aldrich, Milwaukee, WI) were dissolved in 50 μL of warm 5% ethanol/corn 
oil vehicle (Sigma Aldrich), and were intragastrically injected into mouse pups using a 30-
gauge needle. At 10-day post-birth, 1 mg of Avertin (2, 2, 2-tribromoethanol, Sigma 
Aldrich) was intraperitoneally injected into mouse pups for anesthesia, followed by an 
intracardiac perfusion of 8 mL of cold phosphate-buffered saline using a 27-gauge needle. 
The brains were then surgically removed using a standardized procedure and dropped into a 
4% paraformaldehyde fixative solution (Sigma Aldrich). The Cdh5CreERT2 mice were a 
generous gift from Ralf H. Adams. All procedures were performed in accordance with the 
University of Pennsylvania Institutional Animal Care and Use Committee (IACUC) that 
approved all animal protocols.
PdgfbiCreERT2Krit1ECKO and PdgfbiCreERT2Pdcd10 ECKO acute models—The 
endothelial-specific conditional Krit1 null mice were generated by breeding mice expressing 
endothelial specific Pdgfb promoter driven tamoxifen-regulated Cre recombinase, CreERT2, 
in combination with loxP-flanked Krit1 exon 5 (PdgfbCreERT2Krit1fl/fl).38 The endothelial-
specific conditional Pdcd10 null mice were generated by breeding mice expression 
PdgfbCreERT2 in combination with LoxP-flanked Pdcd10 exon 4 (PdgfbCreERT2Pdcd10fl/fl). 
At 1, 2 and 3-day post-birth, mice were intraperitoneally administered 50 μg of tamoxifen 
(Sigma Aldrich) to induce Cre activity and endothelial Krit1 or Pdcd10 gene inactivation in 
the littermates bearing the CreERT2. Mice were sacrificed by decapitation for phenotypic 
analysis on postnatal day 7. Mouse brains were surgically removed and dropped into a 10% 
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neutral buffered formalin fixative solution (Sigma Aldrich). All animal experiments were 
carried out in compliance with animal procedure protocols approved by the University of 
California, San Diego IACUC.
Krit1+/−Msh2−/−, Pdcd10+/−, and Pdcd10+/−Trp53−/− chronic models—Animals 
were generated with the respective genotypes by crossing the Ccm heterozygous mice with 
mice null for Msh2 or Trp53.9, 12, 39 Krit1 heterozygous mice do not manifest any lesions 
unless crossed into these backgrounds. Pdcd10 heterozygous mice manifest a very mild 
phenotype, markedly exaggerated when crossed into Msh2 or Trp53 backgrounds. Mice 
were sacrificed at around 4 months of age by inhalation of carbon dioxide (Airgas, Radnor 
Township, PA, USA) and decapitation. The mouse brains were then surgically extracted and 
dropped into a 10% neutral buffered formalin fixative solution (Azer Scientific, 
Morgantown, PA, USA). All animal protocols were approved by the Duke University 
IACUC, where all breeding of these models was conducted.
Micro-CT acquisition and lesional volumetric assessment
Micro-CT imaging and volumetric assessments of lesion burden were performed using a 
published protocol.40 Fixed extracted brains from the respective models were shipped to the 
University of Chicago, where they were processed by soaking in iodine to increase the 
differential contrast between CCMs and brain tissue on micro-CT images. Brains were then 
scanned using a transmission 180 kV nanofocus X-ray of a Phoenix v|tome|x s micro-
computed tomography system (General Electric, Fairfield, CT, USA).
The post-processing of the micro-CT-scan DICOM images and the volumetric segmentation 
of the iodine-stained CCM lesions were performed using AMIRA 5.5.0 (FEI, Hillsboro, OR, 
USA). In order to correct for variations of total brain volume, the lesional to brain volume 
ratio was calculated.
CCM mouse brain tissue processing
Paraffin-embedded mouse brain tissue blocks of 1-mm thickness were generated at 
University of Chicago Human Tissue Research Center (Chicago, IL, USA). All sections 
were examined at 1.5× magnification for quality and presence of CCMs, using a dissecting 
microscope (Olympus SZ61 mounted with an Olympus DP21 camera). If a lesion was 
present, the block was microsectioned at 5-μm thickness using a rotary microtome (Leica 
Biosystems Inc., Buffalo Grove, IL, USA) until a representative visualization (maximum 
diameter) was encountered by the histotechnicians (TM and RL). When multiple CCM 
lesions were encountered on the same 1-mm thick slice, each lesion was considered 
individually. After hematoxylin and eosin (H&E) staining, all 5-μm sections were reviewed 
for CCMs by two independent observers (RS and TM), with findings further adjudicated by 
a third observer (IAA).8, 9 CCMs were identified and catalogued on the respective coronal 
tissue sections as Stage 1 or Stage 2. A Stage 1 CCM lesion was defined as an isolated 
single ballooned capillary (cavern) with a minimum diameter of 100 μm. Stage 2 CCM 
lesions were contiguous multicavernous lesions with at least one of the caverns having a 
diameter of 100 μm or more (Supplementary Figure 1).8 The lesional area was segmented by 
defining the borders delineating the entire CCM lesion using the polygon area function of a 
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microscope digital camera DP21 (Olympus America Inc., Center Valley, Pennsylvania, 
USA).
Assessment of ROCK activity
Lesional and normal brain capillaries endothelial cells from chronic Krit1+/−Msh2−/− model 
and acute Cdh5iCreERT2Krit1ECKO model were analyzed for ROCK activity. Cells were 
qualitatively assessed for the intensity of phosphorylated myosin light chain (pMLC) and 
defined as either positive (stained brown) or negative (stained blue).8, 9
Perls Prussian blue staining and iron quantification
Sixteen Stage 2 lesions from 13 acute Krit1+/−Msh2−/− mice and 12 Stage 2 lesions from 9 
Cdh5iCreERT2Krit1ECKO mice were stained using Perls Prussian blue to detect non-heme iron 
deposition, an index of chronic hemorrhage burden.8, 9 The stained tissue sections were then 
scanned using a 20X Zeiss objective (Zeiss Microscopy, Göttingen, Germany) mounted on a 
Pannoramic midi II digital slide scanner (3D Histech Ltd, Budapest, Hungary) at the 
Integrated Light Microscopy Facility (University of Chicago, Chicago, IL, USA), and 
exported as magnified TIFF images (5X) from the digital Pannoramic Viewer (3D Histech 
Ltd).
The computational quantification of iron was performed using Image J (National Institute of 
Health, Bethesda, MD, USA). For each exported magnified TIFF images, a RGB color-
deconvolution algorithm was applied to isolate the red, green, blue components.41, 42 The 
blue component image was then selected, inversed and an automatic Rényi entropy-based 
thresholding method applied.43 For each Perls Prussian blue-stained section, the cumulative 
intensity value was assessed based on the clusters that survived the thresholding. The 
cumulative intensity value was then normalized to the lesional area.
Positive B- and T-lymphocytes cells staining
Stage 2 lesions from 9 Krit1+/−Msh2−/− and 5 Cdh5iCreERT2Krit1ECKO mice were stained for 
CD45R/B220 positive B-lymphocytes and CD3 positive T-lymphocytes at the 
immunohistochemistry facility in the human tissue research center at the University of 
Chicago following methods previously reported.8, 9 Sections from spleens were also stained 
for CD45R/B220 positive B-lymphocytes and CD3 positive T-lymphocytes and used as 
positive controls.
Immunofluorescent staining of tight junctional proteins
A double immunofluorescence labeling was performed to study the colocalization in lesions 
and normal vessels of cluster of differentiation 31 (CD31), a specific vascular endothelial 
cell protein, with the 3 tight junctional proteins occludin, zonula occludens 1 (ZO-1) and 
claudin-5. Formalin fixed, paraffin embedded 5μm tissue sections of brain tissues from 2 
acute Cdh5iCreERT2Krit1ECKO and 3 chronic Krit1+/−Msh2−/− mice were deparaffinized by 
successive soaking in xylenes (Thermo Fisher Scientific, Waltham, MA), gradually 
rehydrated in ethanol (dilutions 100, 95, 70 then 50%, Decon Laboratories Inc., King of 
Prussia, PA), and transferred into deionized water. The background autofluorescence was 
quenched by bathing slides in NH4CL for 1 hour, followed by 3 washes in Tris Buffered 
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Saline (TBS, Thermo Scientific). Slides were then transferred into a pH 9 citrate buffer 
(Dako, Santa Clara, CA). Antigen retrieval was performed for 45 minutes using a steamer, 
cooled down for 30 minutes, and then washed three times 5 minutes in TBS.
Sections were then blocked using 0.3% donkey serum for 1 hour at room temperature. 
Primary antibodies were applied at optimized concentrations, as previously determined on 
control tissues. Endothelial cells were identified using a goat anti-mouse CD31 antibody 
(1/500 dilution, R&D Systems, Minneapolis, MN). Junctional proteins were localized using 
rabbit anti-claudin-5 (1/1000, Novus Biologicals, Littleton, CO), rabbit anti-ZO-1 (1/1000 
dilution, Thermo Scientific) or mouse monoclonal anti-occludin conjugated to Alexa Fluor 
594 (1/500 dilution, Thermo Scientific) antibodies.
For dual staining of CD31/claudin-5 or CD31/ZO-1, both pairs of primary antibodies were 
applied overnight at 4° C. CD31 was detected with secondary antibody Alexa Fluor 594 
(donkey anti-goat IgG, Jackson Immunoresearch Laboratories West Grove, PA) and 
claudin-5 and ZO-1 were detected by Alexa Fluor 647 (donkey anti-rabbit IgG, Jackson 
Laboratories).
Dual staining of CD31/occludin was performed sequentially. The detection for each marker 
was completed before application of next antibody. Occludin was detected by direct labeling 
using the anti-occludin Alexa Fluor 594 conjugate and CD31 was detected by the Alexa 
Fluor 647 (donkey anti-goat, Jackson Laboratories).
Between each step, the sections were washed in TBS, 0.1% Tween 20 (Thermo Scientific) 
during 3 cycles of 5 minutes each. In all cases, the result of each negative control confirmed 
the specificity of the corresponding antibody staining.
Specimens were mounted in ProLong Gold (ThermoFisher) antifade medium.
Microscopy of the tight junctional proteins
Z-stack images were acquired at 1.27μm intervals using a fully automated inverted wide 
field Zeiss Axiover 200M microscope (Zeiss Microscopy) with a 63×1.4 numerical aperture 
oil immersion Hamamatsu Orca ER objective (Hamamatsu, Hamamatsu City, Japan), and 
deconvolved through SlideBook 6 (Intelligent Imaging Innovations Inc., Denver, CO) at the 
Integrated Light Microscopy Core facility (University of Chicago, Chicago, IL, USA). The 
z-stack images were exported, and the maximal intensity projection images were generated, 
and overlaid using ImageJ 1.5 (National Institutes of Health, Bethesda, MD, USA), and 
Metamorph 7.0 (Molecular Devices, Sunnyvale, CA, USA) softwares. The number of cells 
positive for CD31, occludin, ZO-1, and claudin-5 were then manually counted on maximal 
projection images.
Statistical methods
The statistical differences between the ratio of CCM lesional per brain volume, the ratio of 
cumulative iron intensity per lesional area in Stage 2 lesions, and the number of 
inflammatory cells per lesional area in Stage 2 lesions of two groups were assessed using an 
Zeineddine et al. Page 6
Lab Invest. Author manuscript; available in PMC 2019 February 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
unpaired two-sample t test or Wilcoxon nonparametric test when appropriate. The equality 
of sample variances was estimated with pooled standard deviation or Satterthwaite method.
Chi-square analyses were performed to compare the prevalence of endothelial cell ROCK 
activity, to assess the distribution of lesions. Chi-square method was also used to compare 
the difference in prevalence of lesional or normal brain capillaries endothelial cells stained 
with occludin, ZO-1 or claudin-5. Statistical analyses and graphics were performed 
respectively using SAS 9.4 (SAS Institute Inc., Cary, NC, USA) and GraphPad Prism 4.0 
(GraphPad Software Inc., La Jolla, CA, USA).
Results
Acute models harbored a higher lesion burden, mainly localized in the cerebellum, than 
chronic models
The acute neonatal model Cdh5iCreERT2Krit1ECKO (n=10) had higher adjusted volume lesion 
burden than the acute PdgfbiCreERT2Krit1ECKO (n=16) (p=0.02), and the chronic 
Krit1+/−Msh2−/− (n=5) models (p=0.009). Krit1+/−Msh2−/− harbored significantly lower 
lesion burden than PdgfbiCreERT2 Krit1ECKO (p=0.001). PdgfbiCreERT2Pdcd10ECKO had 
significantly higher lesion burden than the chronic Pdcd10+/− (p=0.007) model. The 
Pdcd10+/−Trp53−/− model showed a significantly higher lesion burden than the non-
sensitized Pdcd10+/− model (p<0.001) (Figure 1). In addition, Cdh5iCreERT2Krit1ECKO acute 
model showed a predominant distribution of lesions in the cerebellum, while the chronic 
Krit1+/−Msh2−/− model showed a more stochastic distribution (p<0.001) throughout the 
brain (Figure 2).
ROCK activity was differently expressed in the endothelial cells of normal capillaries in 
acute models and chronic models
Lesional endothelial cells and background brain ROCK activity were assessed in acute 
Cdh5iCreERT2Krit1ECKO mice (13 Stage 2 lesions from 3 mice) and in chronic 
Krit1+/−Msh2−/− mice (5 Stage 2 lesions from 3 mice). No significant difference was 
observed in the ROCK activity in Stage 2 lesions between acute and chronic models (Figure 
3A). However, the ROCK activity of Krit1+/−Msh2−/− mice showed a higher prevalence of 
strongly stained endothelial cells in normal brain capillaries located in the forebrain 
compared to the acute Cdh5iCreERT2Krit1ECKO model (p=0.01). The endothelial cells of 
non-lesional brain capillaries located in the hindbrain of acute Cdh5iCreERT2Krit1ECKO 
model showed higher strong ROCK activity (p<0.001) than the endothelial cells of normal 
brain capillaries in the forebrain (Figure 3B).
The iron deposition was higher in the Stage 2 lesions of chronic models
The Stage 2 lesions of chronic Krit1+/−Msh2−/− (16 Stage 2 lesions from13 mice) showed a 
higher ratio of cumulative iron intensity per lesional area (p=0.03) compared to the acute 
Cdh5iCreERT2Krit1ECKO (12 Stage 2 lesions from 9 mice) (Figure 4).
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The Stage 2 lesions of chronic models showed a higher number of inflammatory cells
The chronic Krit1+/−Msh2−/− Stage 2 lesions (9 Stage 2 lesions from 9 mice) showed a 
higher number of B cells (p=0.005) and T cells (p=0.04) per lesional area compared to the 
acute Cdh5iCreERT2Krit1EKCO Stage 2 lesions (14 Stage 2 lesions from 5 mice) (Figure 5).
The prevalence of lesional endothelial cells expressing occludin was lower in acute and 
chronic models, than in non lesional capillaries. The prevalence of lesional endothelial 
cells expressing ZO-1 was decreased only in chronic models compared to normal 
capillaries
The number of endothelial cells expressing CD31, occludin, ZO-1 and claudin-5 were 
assessed manually in both acute Cdh5iCreERT2Krit1ECKO (n=2) and chronic Krit1+/−Msh2−/− 
(n=3) mice (Supplementary Table 1). The percentage of CD31 positive endothelial cells 
expressing occludin was lower in CCM lesions than in normal vessels in both acute 
(p<0.0001) and chronic (p=0.005) models (Figure 6A). In chronic models, the proportion of 
cell expressing both CD31 and ZO-1 was also lower in lesions than normal vessels 
(p<0.0001) (Figure 6B). However, no difference was observed in the prevalence of claudin-5 
immunopositive endothelial cells either between acute and chronic model lesions, or 
between CCM lesions and normal vessels.
Discussion
We herein described phenotypic differences between acute and chronic CCM mouse models, 
reflecting different pathogenetic features of CCM disease (Table 1). While the fundamental 
signaling alterations of endothelial ROCK activity and relative loss of Occludin in tight 
junctions were present in both, many other integral pathologies, namely iron deposition and 
immune cell infiltration, were not observed in the acute neonatal models, nor was the 
endothelial loss of a second junctional protein ZO-1.
Lesions in the heterozygous chronic models form stochastically over time, randomly 
distributed throughout the mouse brain, much like human lesions.44, 45 They harbor other 
documented phenotypic markers of the human lesion such as iron deposition and immune 
cell infiltration.9, 22, 23 Similar to the human form of the disease, there is a much heavier 
lesion burden with Pdcd10 mutations than with other genotypes.33, 39, 46 Chronic models of 
the 3 Ccm genes9, 47 have been used successfully to test the effect of various investigational 
drugs on lesion formation, maturation and bleeding.8, 28 But these models are rather 
inefficient, developing a negligible lesion burden except when sensitized with complex 
breeding, and only one of eight mice achieving the desired genotype. Potential impact of the 
sensitized background (Msh2 or Tp53 loss) on the disease biology could not be excluded.
The acute models examined herein had much higher lesion burden than the chronic model, 
consistent with induced loss of gene function in angiogenically active endothelial cells in the 
developing hindbrain, rather than in a volume random distribution throughout the brain.
13, 14, 37
. The lesion burden in acute models is likely a reflection of the efficiency and timing 
of the knockout as well as the time of sacrifice of the animals. Other groups have reported 
models of the disease using an inducible knockout with lower lesion burdens, surviving later 
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in life. This variability may be explained by a less efficient knockout induction, lower 
aggressiveness of Ccm2 genotype, or the induction of gene loss later in the mouse’s life.
32, 33, 36
We observed that both models had ROCK activity in a similar proportion of lesional 
endothelial cells. However, the chronic model background brain endothelial cells had a 
higher proportion of cells with increased ROCK activity. This is consistent with the 
heterozygous state of the chronic model in which every endothelial cell harbors only one 
functional gene from the time of embryogenesis. Conversely, ROCK activity in normal 
capillary endothelium was increased in the hindbrain but not forebrain of acute models, 
consistent with the loss of Ccm gene function in these regions of the brain with angiogenic 
activity. Staining for Ccm proteins was not performed in these experiments, but this is 
currently being pursued in a larger project, looking at clonal versus mosaic loss of gene 
function and deterministic lesion development.
Lesions from acute models showed minimal iron deposition consistent with the absence of 
chronic hemorrhage. This may be related to the early sacrifice of these animals secondary to 
the high lesion burden. Other models of inducible knockout where animals survived later in 
life did in fact show some iron deposition in the older animals.33, 36, 48 We also described a 
limited inflammatory response in acute lesions. This may be explained by an immature 
neonatal immune system,49 or by the immune response potentially developing over time, or 
in reaction to chronic hemorrhage. Hence, signaling and molecular alterations related to 
bleeding and inflammation might thus be either underrepresented or missing altogether in 
the acute models. Interventions targeting chronic bleeding and inflammatory mechanisms 
influencing lesion development cannot be tested, and novel targets of therapy may be missed 
by solely relying on these neonatal models. This is particularly cogent with the recent 
evidence of the potential role of immune-modulation as CCM therapy,26 and the impact of 
statins on iron deposition in CCM.28
We observed a lower proportion of endothelial cells expressing occludin immunopositivity 
in the lining of lesions of both acute and chronic models in comparison to non-lesional 
capillary endothelium. We also found a lower proportion of lesional endothelial cells with 
ZO-1 expression in chronic models. The mRNA expression of occludin, claudin-5, ZO-1 has 
been reported to be downregulated in resected human CCM lesion.50 ROCK mediates the 
formation of the tight junctions by phosphorylating occludin and claudins to regulate 
permeability through endothelial cell monolayers.10, 51, 52 In vitro and in vivo studies 
demonstrated that pro-inflammatory processes downregulate the expression of ZO-1, and 
increase blood-brain barrier permeability.53–56 Our collaborators reported a loss of ZO-1 
expression with Krit1 loss in cultured brain microvascular endothelial cells.57 The results 
herein demonstrate a gross disruption of junctional protein expression in a fraction of 
endothelial cells lining CCM lesions in murine brains. The loss of tight junction proteins is 
more overt in chronic lesions, involving both occludin and ZO-1, perhaps reflecting a 
process of lesion maturation.
Overall, we describe a number of key phenotypic differences between acute and chronic 
models. Acute models will remain highly valuable, with advantages of efficient and quick 
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lesion development, allowing the characterization of fundamental signaling aberrations 
driving CCM lesion formation. Conversely, chronic models are less efficient at developing 
lesions, but reflect more faithfully other features of lesion maturation, including chronic 
hemorrhage and inflammation, and stochastic lesion development over time. They allow 
more reliable testing of therapies targeting these clinically relevant features of the human 
disease.
Chronic models develop Stage1 and Stage 2 lesions stochastically over time, hence using 
them at an earlier age would not yield significant lesion burden for meaningful study. 
Conversely, acute models (except with the milder Ccm2 genotype) do not typically survive 
into adulthood or are very ill in view of severity of hindbrain lesion burden. We foresee the 
development of new hybrid models, seeking to induce gene loss less efficiently, or later 
postnatally. This could create a burden of lesions that increases stochastically over time, and 
allows lesions to develop mature features of chronic hemorrhage and inflammation, 
potentially recapitulating advantages of both models.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Volumetric assessment of lesion burden using micro-CT
Cdh5iCreERT2 Krit1ECKO acute mice (n=10) had higher adjusted volume lesion burden than 
the acute PdgfbiCreERT2 Krit1ECKO (n=16), and the chronic Krit1+/−Msh2−/− (n=5). 
Pdcd10+/− Trp53−/− showed a significantly higher lesion burden than the non-sensitized 
PdgfbiCreERT2 Pdcd10ECKO (n=4) and Pdcd10+/− (n=21). All p values were considered to be 
statistically significant at *p<0.05, **p<0.01 or ***p<0.001.
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Figure 2. Volume distribution of lesions
Acute Cdh5iCreERT2Krit1ECKO mice harbor proportionally more lesion within the 
cerebellum compared to chronic Krit1+/−Msh2−/− mice that have a more stochastic 
distribution (p<0.001). Example of a 3D rendering of an acute model (top) showing the 
highly-concentrated lesion burden in the cerebellum compared to the more stochastic 
distribution in a chronic brain model (bottom). All p values were considered to be 
statistically significant at ***p<0.001.
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Figure 3. Endothelial Rho kinase protein (ROCK) activity in Stage 2 lesions and brain capillaries
(A) (Left) No significant difference was observed between the ROCK activity in endothelial 
cells of acute Cdh5iCreERT2Krit1ECKO (n=93 cells counted in 5 lesions from 3 mice) and 
chronic Krit1+/−Msh2−/− lesions (n=358 cells counted in 13 lesions from 3 mice). (Right) 
Representative image of a Stage 2 lesion stained for ROCK activity showing an endothelial 
cell with strong ROCK activity (brown staining; black arrowhead) and another with no 
ROCK activation (blue staining; white arrowhead). Scale bar is 50 μm. (B) (Left) 
Krit1+/−Msh2−/− brain normal capillaries (n=583 cells from 3 mice) had a significantly 
higher (p=0.01) strong ROCK activity compared to Cdh5iCreERT2Krit1ECKO normal 
capillaries (n=445 cells from 3 mice) far from lesions in the forebrain. Endothelial cells of 
Cdh5iCreERT2Krit1ECKO (n=179 cells from 3 mice) normal capillaries near lesions in the 
hindbrain had higher strong activity (p<0.001) than those far (n=445 cells from 3 mice) from 
lesions in the forebrain. (Right) Representative image of a normal capillary stained for 
ROCK activity. Scale bar is 20 μm. All p values were considered to be statistically 
significant at **p<0.01 or ***p<0.001.
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Figure 4. Non-heme iron deposition in Stage 2 CCM lesions in acute and chronic models
(A) Lesions from chronic Krit1+/−Msh2−/− (16 lesions from 13 mice) harbor significantly 
higher (p=0.03) integrated density of non-heme iron deposition per lesional area compared 
to lesions from acute Cdh5iCreERT2Krit1ECKO (12 lesions from 9 mice). (B) Representative 
non-heme iron deposition (Perls blue stain) in Stage 2 lesions from an acute 
Cdh5iCreERT2Krit1ECKO model (upper) and a chronic Cdh5iCreERT2Krit1ECKO model 
(lower). Scale bars are 200 μm. All p values were considered to be statistically significant at 
*p<0.05.
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Figure 5. Inflammatory cells in Stage 2 lesions in acute and chronic CCM models
(A) (Left) Chronic Krit1+/−Msh2−/−lesions (9 lesions from 9 mice) showed a significantly 
higher (p=0.005) number of B cells per lesional area than the Cdh5iCreERT2Krit1ECKO acute 
lesions (14 lesions from 5 mice). (Right) Representative image of a Stage 2 showing brown 
stained CD45R/B220 B cells in a chronic Krit1+/−Msh2−/− Stage 2 lesion. (B) (Left) Chronic 
Krit1+/−Msh2−/− lesions (9 lesions from 9 mice) showed a significantly higher (p=0.04) 
number of T cells per lesional area than the Cdh5iCreERT2Krit1ECKO acute lesions (14 
lesions from 5 mice). (Right) Representative image of a Stage 2 showing staining of CD3 
positive T cells in a chronic Krit1+/−Msh2−/− Stage 2 lesion. Scale bars are 50 μm. All p 
values were considered to be statistically significant at *p<0.05 or **p<0.01.
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Figure 6. Disrupted tight junctions in acute and chronic CCM models
(A) The difference of CD31 positive endothelial cells (green channel) expressing occludin 
(red channel) and those lacking occludin was lower in CCM lesions compared to normal 
vessels for both acute (p<0.0001) and chronic (p=0.005) models. (B) The difference of cells 
expressing both CD31 (green channel) and ZO-1 (red channel) and those expressing only 
CD31 was also lower in CCM lesions compared to normal vessels (p<0.0001) only in 
chronic models. The white arrows indicate endothelial cell lacking junctional proteins. * 
indicate the lumen of the CCM lesion. Scale bars are 20 μm (on the images). All p values 
were considered to be statistically significant at **p<0.01 or ***p<0.001 (on the graphs).
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